Showing results (461-470 of 583) with videos related to

Sort By:
Pageof 59
Cancer Science|October 23, 2024
FOXP3+/CD8+ ratio associated with aggressive behavior in RUNX3-methylated diffuse esophagogastric junction tumorSuguru Maruyama, Yu Imamura, Tasuku Toihata, et al.
Surgery Today|May 4, 2018
Effect of early oral feeding on length of hospital stay following gastrectomy for gastric cancer: a Japanese multicenter, randomized controlled trialNobuyuki Shimizu, Eiji Oki, Yutaka Tanizawa, et al.
International Journal of Cancer|August 5, 2015
Lysine-specific demethylase-1 contributes to malignant behavior by regulation of invasive activity and metabolic shift in esophageal cancerKeisuke Kosumi, Yoshifumi Baba, Akihisa Sakamoto, et al.
Cancer Chemotherapy and Pharmacology|November 27, 2019
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501BSatoshi Yuki, Katsunori Shinozaki, Tomomi Kashiwada, et al.
Annals of Surgical Oncology|July 6, 2025
Cytotoxic Anti-tumor Drugs and Tumor-Associated Macrophages Synergistically Surge PD-L1 Expression in Esophageal Squamous Cell CarcinomaKosuke Hirose, Hajime Otsu, Takaaki Masuda, et al.
Journal of Gastroenterology and Hepatology|August 18, 2018
C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancerKensuke Kudou, Hiroshi Saeki, Yuichiro Nakashima, et al.
Oncology|March 8, 2018
Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402)Hiroaki Tanioka, Yuji Miyamoto, Akihito Tsuji, et al.
Scientific Reports|January 19, 2018
Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung AdenocarcinomaSeijiro Sato, Masayuki Nagahashi, Terumoto Koike, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2022
A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701Kazuma Kobayshi, Koichi Suyama, Hiroo Katsuya, et al.
BMC Cancer|August 22, 2023
NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastasesShin Kobayashi, Hideaki Bando, Akinobu Taketomi, et al.
Pageof 59